Patent intelligence · US
US 10898585
Gene therapy for AADC deficiency
Gene therapy for AADC deficiency
Patent details — US 10898585
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 26, 2021
- Expiration
- Jan 21, 2041
- Applicant
- PTC THERAPEUTICS, INC.
- Claims
- 26
- CPC classes
- A61K, A61K31/4515, A61K31/5513, A61K48/00
Quick answer
US 10898585 (Gene therapy for AADC deficiency) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Jan 26, 2021. Expires Jan 21, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PTC THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K31/4515, A61K31/5513, A61K48/00, A61K48/005, A61K48/0075
More from PTC THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12398140
Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
granted -
US 12384789
Compounds for treating Huntington's disease
granted -
US 12384797
Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
granted -
US 12281083
2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof
granted -
US 12139499
Heteroaryl compounds for treating Huntington's disease
granted -
US 12103926
Compounds for treating huntington's disease
granted -
US 12023335
Method for treating pancreatic cancer
granted -
US 11938101
Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
granted
Frequently asked questions
What is US patent 10898585?
US 10898585 (Gene therapy for AADC deficiency) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted Jan 26, 2021. Expires Jan 21, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10898585?
PTC THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 149 pharmaceutical patents for this assignee.
When does US 10898585 expire?
Our index shows an expiration date of Jan 21, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.